Endothelial function measurement

OTHER2 trials

Sponsors

Jean-Luc Balligand, University Hospital, Bordeaux

Conditions

Cluster HeadacheHypertrophy, Left Ventricular

Phase 2

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

CompletedNCT02599480

Jean-Luc BalligandHypertrophy, Left Ventricular

Start: 2016-09-12End: 2022-02-16Updated: 2025-02-10

Unknown Phase

Cluster Headache, Addictions and Vascular Function

CompletedNCT02640105

University Hospital, BordeauxCluster Headache

Start: 2014-06-25End: 2016-06-10Updated: 2022-03-31

Related Papers

Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.

2025-03-226 citations

Repurposing the β<sub>3</sub>-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease

JAMA Cardiology2023-09-209 citations